- NMPA Clinical Evaluation
- The Blood Oxygen Module Used In Combination With Ventilators Shall Be Clinically Evaluated Through Laboratory Human Study. If The Product Is Not Marketed In China, Whether The Racial Difference (difference In Skin Color Evaluation) Shall Be Considered In This Evaluation?
- If A Registered Product Does Not Apply For Renewal Registration Within The Specified Time, Can The Original Registered Product Be Selected As The Predicate For Clinical Evaluation When Applying For A New Registration And How Should Clinical Data Be Provided?
- If The Products That Use CER Or Clinical Trial Pathway For Clinical Evaluation Have Been Listed In The Published Exemption Directory During The Review, Can The Clinical Evaluation Pathway Be Changed When The Applicant Supplements The Dossier?
- When The Overseas Applicant Carries Out Clinical Evaluation Through The Clinical Trial Path, If The Overseas Clinical Trial Data Is Provided, Is It Still Necessary To Carry Out Clinical Trials In China?
- Is There A Requirement For The Clinical Evaluation To Assess Comparable Or Similar Devices Even If You Do Not Plan To Utilize Equivalency As A Route To Conformity?
- Are Clinical Evaluations Required For Products Already Approved Or Is This Requirement Only For New Products?
- China Vs EU Comparison: The Chart Says Clinical Evaluation Exemption Catalog: Is The Clinical Trial Exemption Catalog Meant? Is It The Same?
- How Often Do You Expect NMPA To Require The Periodic Required Clinical Evaluations (e.g. 1x/year, 1x/5 Years)?